tiprankstipranks
Trending News
More News >
Shin Nippon Biomedical Laboratories, Ltd. (JP:2395)
:2395
Japanese Market
Advertisement

Shin Nippon Biomedical Laboratories, Ltd. (2395) Stock Statistics & Valuation Metrics

Compare
2 Followers

Total Valuation

Shin Nippon Biomedical Laboratories, Ltd. has a market cap or net worth of ¥58.70B. The enterprise value is ¥79.14B.
Market Cap¥58.70B
Enterprise Value¥79.14B

Share Statistics

Shin Nippon Biomedical Laboratories, Ltd. has 41,632,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,632,400
Owned by Insiders
Owned by Institutions

Financial Efficiency

Shin Nippon Biomedical Laboratories, Ltd.’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 3.22%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)3.22%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee22.25M
Profits Per Employee3.38M
Employee Count1,457
Asset Turnover0.35
Inventory Turnover1.26

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio11.9
PS Ratio0.00
PB Ratio1.42
Price to Fair Value1.49
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio-33.44

Income Statement

In the last 12 months, Shin Nippon Biomedical Laboratories, Ltd. had revenue of 32.41B and earned 4.92B in profits. Earnings per share was 118.30.
Revenue32.41B
Gross Profit16.57B
Operating Income2.99B
Pretax Income6.01B
Net Income4.92B
EBITDA8.83B
Earnings Per Share (EPS)118.30

Cash Flow

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00

Dividends & Yields

Shin Nippon Biomedical Laboratories, Ltd. pays an annual dividend of ¥20, resulting in a dividend yield of 3.55%
Dividend Per Share¥20
Dividend Yield3.55%
Payout Ratio42.27%
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.02
52-Week Price Change18.12%
50-Day Moving Average1.36K
200-Day Moving Average1.43K
Relative Strength Index (RSI)56.43
Average Volume (3m)216.30K

Important Dates

Shin Nippon Biomedical Laboratories, Ltd. upcoming earnings date is Aug 5, 2025, TBA (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 5, 2025
Ex-Dividend DateSep 29, 2025

Financial Position

Shin Nippon Biomedical Laboratories, Ltd. as a current ratio of 1.13, with Debt / Equity ratio of 86.14%
Current Ratio1.13
Quick Ratio0.69
Debt to Market Cap0.57
Net Debt to EBITDA2.54
Interest Coverage Ratio14.72

Taxes

In the past 12 months, Shin Nippon Biomedical Laboratories, Ltd. has paid 1.15B in taxes.
Income Tax1.15B
Effective Tax Rate0.19

Enterprise Valuation

Shin Nippon Biomedical Laboratories, Ltd. EV to EBITDA ratio is 9.29, with an EV/FCF ratio of -21.48.
EV to Sales2.53
EV to EBITDA9.29
EV to Free Cash Flow-21.48
EV to Operating Cash Flow11.66

Balance Sheet

Shin Nippon Biomedical Laboratories, Ltd. has ¥10.06B in cash and marketable securities with ¥34.09B in debt, giving a net cash position of ¥24.03B billion.
Cash & Marketable Securities¥10.06B
Total Debt¥34.09B
Net Cash¥24.03B
Net Cash Per Share¥577.21
Tangible Book Value Per Share¥912.33

Margins

Gross margin is 51.12%, with operating margin of 9.21%, and net profit margin of 15.19%.
Gross Margin51.12%
Operating Margin9.21%
Pretax Margin18.55%
Net Profit Margin15.19%
EBITDA Margin27.23%
EBIT Margin19.18%

Analyst Forecast

The average price target for Shin Nippon Biomedical Laboratories, Ltd. is ¥1,620.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target¥1,620.00
Price Target Upside14.89% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast22.55%
EPS Growth Forecast-10.96%

Scores

Smart ScoreN/A
AI Score69.5
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis